Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Effective 1 de abril, 2022, criteria used for medical necessity review of Oncotype DX Breast for commercial products can be found in this medical policy and will no longer be in the online authorization tool. Please refer to the draft medical policy for coding and other details here.